Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

novartis_pic

Novartis acquires Admune Therapeutics

October 21, 2015
Research and Development Admune Therapeutics, Cancer, Novartis, Palobiofarma, immunotherapy

Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …

News
WHO flag

Novartis and Biogen launch drug access programmes in developing countries

October 15, 2015
Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid

Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries.  The Swiss firm has …

News
gamidi_cell_logo

Novartis invests further $15m into Gamida Cell

October 13, 2015
Research and Development, Sales and Marketing Gamida Cell, Novartis, pharma mergers and acquisitions

Novartis is to invest an extra $15 million into Israeli stem cell therapy developer Gamida Cell, adding an additional 2.5% …

News
Psoriasis

Novartis psoriasis drug shows three-year efficacy

October 12, 2015
Cosentyx, EADV, Novartis, Secukinumab, psoriasis

Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …

News
sandoz_building

FDA accepts Sandoz submission for Amgen biosimilar

October 2, 2015
Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars

Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …

News
novartissunlight_copy

Novartis’s secukinumab meets Phase 3 goals

October 1, 2015
Research and Development Novartis, Secukinumab, arthritis

Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …

News
novartis

Study shows Novartis’s Afinitor positively reduces tumors

September 30, 2015
Research and Development Afinitor, Novartis

Novartis has announced the results of a Phase III pivotal study, showing Afinitor (everolimus) tablets reduced the risk of progression …

News

Novartis’ new heart failure medicine recommended for EU approval

September 25, 2015
Medical Communications, Research and Development Entresto, Novartis, eams, heart failure

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

News
novartis_access_ncds_facts

Novartis launches affordable medicines portfolio for lower-income countries

September 24, 2015
Manufacturing and Production, Sales and Marketing Novartis

Novartis has announced the launch of ‘Novartis Access’, a portfolio of 15 medicines to treat chronic diseases in low and …

News
BioInject

Sandoz opens €150m manufacturing facility

September 18, 2015
Manufacturing and Production Austria, BioInject, Novartis, Sandoz

Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria.  Known as BioInject will result in the creation …

News
Farydak

NICE rejects Farydak for multiple myeloma

September 16, 2015
Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News
zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

News
Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015
Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025